

Urinary Tract Infection Market Forecasts to 2034 – Global Analysis By Product (Azoles and Amphotericin B, Cephalosporin, Nitrofurans, Penicillin and Combinations, Quinolones and Other Products), Treatment Type, Test Type, Indication, Distribution Channel, End User and By Geography

<https://marketpublishers.com/r/UFBCFCF4851CEN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: UFBCFCF4851CEN

Abstracts

According to Statistics MRC, the Global Urinary Tract Infection Market is accounted for \$8.2 billion in 2026 and is expected to reach \$14.9 billion by 2034 growing at a CAGR of 7.67% during the forecast period. Urinary Tract Infections is a test of urine to detect and manage a wide range of disorders, such as urinary tract infections, kidney disease and diabetes. UTIs, caused primarily by bacteria entering the urethra and multiplying in the urinary tract, are common medical conditions. It serves the healthcare sector by providing diagnostic tools, antibiotics, and therapeutics tailored for UTI management.

According to the American Academy of Family Physicians (AAFP), in March 2020, by Leonardo Ferreira, kidney stones were a common ailment, with an annual incidence of eight instances per 1,000 persons. As per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 men per year.

Market Dynamics:

Driver:

Increasing prevalence of urinary tract infections

The increasing prevalence of urinary tract infections (UTIs), especially in women, the elderly, and people with weakened immune systems, is driving up demand for diagnostic and treatment options. The aging population, increased knowledge of UTIs, and a growing emphasis on early detection and timely treatment are some of the factors driving the UTI market's growth. Furthermore, the need for novel diagnostics, antibiotics, and preventive measures is highlighted by this market driver, which encourages investment and research in the creation of fresh goods and remedies for UTIs.

Restraint:

Rising instances of antibiotic resistance

Effective treatment of urinary tract infections is becoming more difficult due to the emergence of resistant bacterial strains caused by the overuse and misuse of antibiotics. The need for new therapeutic solutions arises from the fact that this resistance limits the effectiveness of current antibiotics and complicates standard treatment regimens. In order to combat antibiotic resistance in UTI management, research and development efforts must be concentrated in order to find new medications and alternative treatment modalities.

Opportunity:

Adoption of novel diagnostic technologies

Point-of-care diagnostics and rapid molecular testing are instances of advanced diagnostic tools that can help identify UTIs more quickly and accurately. This helps to effectively use antibiotics, addressing the growing concern of antibiotic resistance, and improves patient care by enabling timely treatment. Businesses that invest in cutting-edge UTI diagnostic solutions will profit from the growing need for accurate and efficient diagnostic techniques, which will enhance overall healthcare outcomes and lessen the financial burden of UTI treatment.

Threat:

Lack of awareness

UTIs, common bacterial infections affecting the urinary system, often go undetected due to insufficient public knowledge about their causes, symptoms, and preventive

measures. This dearth of awareness hampers early diagnosis and timely medical intervention, leading to complications and increased healthcare costs. However, misconceptions and inadequate information about hygiene practices contribute to the prevalence of UTIs. The lack of awareness not only affects individual health outcomes but also burdens healthcare systems.

Covid-19 Impact:

The overwhelming focus on managing and containing the virus has diverted healthcare resources, attention, and funding away from other medical conditions, including UTIs. Lockdowns, restricted healthcare access, and patient concerns about visiting medical facilities have led to delayed diagnoses and treatments, exacerbating the severity of UTIs. Moreover, the increased use of antibiotics to treat Covid-19-related bacterial infections has contributed to antibiotic resistance, potentially limiting the effectiveness of standard UTI treatments. Supply chain disruptions have also affected the availability of UTI medications and diagnostics.

The antibiotics segment is expected to be the largest during the forecast period

The antibiotics segment expected to have largest share over the anticipated period. A wide variety of medications are used to treat bacterial infections of the urinary tract in the Urinary Tract Infection market's antibiotics segment. Beta-lactam antibiotics, like amoxicillin, and fluoroquinolones, like ciprofloxacin, are frequently prescribed antibiotics for urinary tract infections. Additionally, the goals of ongoing research and development are to reduce side effects, minimize resistance, and improve the effectiveness of these antibiotics.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

Clinical laboratories segment in the urinary tract infection market is expected to have profitable growth. Clinical laboratories are pivotal in the identification and confirmation of UTIs through the analysis of urine samples, which includes assessing bacterial presence and determining antibiotic susceptibility. These laboratories utilize advanced technologies and testing methods to ensure accurate and timely results, facilitating prompt medical intervention. Moreover, the adoption of automation and molecular diagnostic techniques within these laboratories enhances the efficiency and precision of UTI diagnostics.

Region with largest share:

The Asia-Pacific Urinary Tract Infection market is expanding substantially due to the need for diagnostic and treatment solutions is being driven by rising healthcare costs, better healthcare infrastructure, and increased awareness of UTIs. The increased frequency of UTIs is also attributed to a changing lifestyle and an aging population. Additionally, favourable government initiatives and the growth of pharmaceutical and healthcare companies are driving the regional growth.

Region with highest CAGR:

The market for urinary tract infections is expanding substantially in Europe due to a growing geriatric population and rising public awareness. The market is growing due to risk factors like diabetes and urine incontinence are becoming more common, which is also driving growth in Europe. Additionally, government campaigns to raise awareness of urinary health issues and encourage preventative measures have been crucial in driving market growth in the European Union.

Key players in the market

Some of the key players in Urinary Tract Infection market include Abbott Laboratories , Acon Laboratories, Inc., Allergan Plc, Arkray, Inc., Astrazeneca Plc, Bayer Ag , Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Elektronika Kft., F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co. Inc, Mindray Medical International Limited, Novartis Ag, Pfizer Inc, Roche Diagnostics, Sanofi S.A., Siemens Healthcare, Sysmex Corporation and Urit Medical Electronic Group Co., Ltd.

Key Developments:

In December 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The Agreement is based on a basic agreement on business collaboration in the field of immunoassay. Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

In December 2023, AstraZeneca Pharma India has entered into a Memorandum of Understanding (MoU) with Roche Diagnostics India to enhance diagnostics for breast

cancer patients, particularly focusing on refining HER2 diagnostics with the latest advancements. This strategic alliance aligns with AstraZeneca's commitment to advancing patient-centric healthcare solutions and Roche Diagnostics' dedication to pioneering diagnostic innovation.

Products Covered:

Azoles and Amphotericin B

Cephalosporin

Nitrofurans

Penicillin and Combinations

Quinolones

Other Products

Treatment Types Covered:

Antibiotics

Analgesics

Antispasmodics

Other Treatment Types

Test Types Covered:

Microscopic Urinary Tract Infections

Biochemical Urinary Tract Infections

Flow Cytometric Urinary Tract Infections

Other Test Types

Indications Covered:

Complicated Urinary Tract Infection

Neurogenic Bladder Infections

Recurring Complicated Urinary Tract Infection

Uncomplicated Urinary Tract Infection

Other Indications

Distribution Channels Covered:

Drug Stores

Gynaecology and Urology Clinics

Retail Pharmacies

Other Distribution Channels

End Users Covered:

Hospitals

Clinical Laboratories

Home Healthcare

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL URINARY TRACT INFECTION MARKET, BY PRODUCT

- 5.1 Introduction
- 5.2 Azoles and Amphotericin B
- 5.3 Cephalosporin
- 5.4 Nitrofurans
- 5.5 Penicillin and Combinations
- 5.6 Quinolones
- 5.7 Other Products

6 GLOBAL URINARY TRACT INFECTION MARKET, BY TREATMENT TYPE

- 6.1 Introduction
- 6.2 Antibiotics
- 6.3 Analgesics
- 6.4 Antispasmodics
- 6.5 Other Treatment Types

7 GLOBAL URINARY TRACT INFECTION MARKET, BY TEST TYPE

- 7.1 Introduction
- 7.2 Microscopic Urinary Tract Infections
- 7.3 Biochemical Urinary Tract Infections
- 7.4 Flow Cytometric Urinary Tract Infections
- 7.5 Other Test Types

8 GLOBAL URINARY TRACT INFECTION MARKET, BY INDICATION

- 8.1 Introduction
- 8.2 Complicated Urinary Tract Infection
- 8.3 Neurogenic Bladder Infections
- 8.4 Recurring Complicated Urinary Tract Infection
- 8.5 Uncomplicated Urinary Tract Infection
- 8.6 Other Indications

9 GLOBAL URINARY TRACT INFECTION MARKET, BY DISTRIBUTION CHANNEL

- 9.1 Introduction
- 9.2 Drug Stores

9.3 Gynaecology and Urology Clinics

9.4 Retail Pharmacies

9.5 Other Distribution Channels

10 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER

10.1 Introduction

10.2 Hospitals

10.3 Clinical Laboratories

10.4 Home Healthcare

10.5 Other End Users

11 GLOBAL URINARY TRACT INFECTION MARKET, BY GEOGRAPHY

11.1 Introduction

11.2 North America

11.2.1 US

11.2.2 Canada

11.2.3 Mexico

11.3 Europe

11.3.1 Germany

11.3.2 UK

11.3.3 Italy

11.3.4 France

11.3.5 Spain

11.3.6 Rest of Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 New Zealand

11.4.6 South Korea

11.4.7 Rest of Asia Pacific

11.5 South America

11.5.1 Argentina

11.5.2 Brazil

11.5.3 Chile

11.5.4 Rest of South America

11.6 Middle East & Africa

11.6.1 Saudi Arabia

11.6.2 UAE

11.6.3 Qatar

11.6.4 South Africa

11.6.5 Rest of Middle East & Africa

12 KEY DEVELOPMENTS

12.1 Agreements, Partnerships, Collaborations and Joint Ventures

12.2 Acquisitions & Mergers

12.3 New Product Launch

12.4 Expansions

12.5 Other Key Strategies

13 COMPANY PROFILING

13.1 Abbott Laboratories

13.2 Acon Laboratories, Inc.

13.3 Allergan Plc

13.4 Arkray, Inc.

13.5 Astrazeneca Plc

13.6 Bayer Ag

13.7 Beckman Coulter, Inc.

13.8 Bio-Rad Laboratories, Inc.

13.9 Elektronika Kft.

13.10 F. Hoffmann-La Roche Ltd

13.11 Glaxosmithkline Plc

13.12 Johnson & Johnson

13.13 Merck & Co. Inc

13.14 Mindray Medical International Limited

13.15 Novartis Ag

13.16 Pfizer Inc

13.17 Roche Diagnostics

13.18 Sanofi S.A.

13.19 Siemens Healthcare

13.20 Sysmex Corporation

13.21 Urit Medical Electronic Group Co., Ltd.

List Of Tables

LIST OF TABLES

- Table 1 Global Urinary Tract Infection Market Outlook, By Region (2023–2034) (\$MN)
- Table 2 Global Urinary Tract Infection Market Outlook, By Product (2023–2034) (\$MN)
- Table 3 Global Urinary Tract Infection Market Outlook, By Azoles and Amphotericin B (2023–2034) (\$MN)
- Table 4 Global Urinary Tract Infection Market Outlook, By Cephalosporin (2023–2034) (\$MN)
- Table 5 Global Urinary Tract Infection Market Outlook, By Nitrofurans (2023–2034) (\$MN)
- Table 6 Global Urinary Tract Infection Market Outlook, By Penicillin and Combinations (2023–2034) (\$MN)
- Table 7 Global Urinary Tract Infection Market Outlook, By Quinolones (2023–2034) (\$MN)
- Table 8 Global Urinary Tract Infection Market Outlook, By Other Products (2023–2034) (\$MN)
- Table 9 Global Urinary Tract Infection Market Outlook, By Treatment Type (2023–2034) (\$MN)
- Table 10 Global Urinary Tract Infection Market Outlook, By Antibiotics (2023–2034) (\$MN)
- Table 11 Global Urinary Tract Infection Market Outlook, By Analgesics (2023–2034) (\$MN)
- Table 12 Global Urinary Tract Infection Market Outlook, By Antispasmodics (2023–2034) (\$MN)
- Table 13 Global Urinary Tract Infection Market Outlook, By Other Treatment Types (2023–2034) (\$MN)
- Table 14 Global Urinary Tract Infection Market Outlook, By Test Type (2023–2034) (\$MN)
- Table 15 Global Urinary Tract Infection Market Outlook, By Microscopic Urinary Tract Infections (2023–2034) (\$MN)
- Table 16 Global Urinary Tract Infection Market Outlook, By Biochemical Urinary Tract Infections (2023–2034) (\$MN)
- Table 17 Global Urinary Tract Infection Market Outlook, By Flow Cytometric Urinary Tract Infections (2023–2034) (\$MN)
- Table 18 Global Urinary Tract Infection Market Outlook, By Other Test Types (2023–2034) (\$MN)
- Table 19 Global Urinary Tract Infection Market Outlook, By Indication (2023–2034)

(\$MN)

Table 20 Global Urinary Tract Infection Market Outlook, By Complicated Urinary Tract Infection (2023–2034) (\$MN)

Table 21 Global Urinary Tract Infection Market Outlook, By Neurogenic Bladder Infections (2023–2034) (\$MN)

Table 22 Global Urinary Tract Infection Market Outlook, By Recurring Complicated Urinary Tract Infection (2023–2034) (\$MN)

Table 23 Global Urinary Tract Infection Market Outlook, By Uncomplicated Urinary Tract Infection (2023–2034) (\$MN)

Table 24 Global Urinary Tract Infection Market Outlook, By Other Indications (2023–2034) (\$MN)

Table 25 Global Urinary Tract Infection Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 26 Global Urinary Tract Infection Market Outlook, By Drug Stores (2023–2034) (\$MN)

Table 27 Global Urinary Tract Infection Market Outlook, By Gynaecology and Urology Clinics (2023–2034) (\$MN)

Table 28 Global Urinary Tract Infection Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 29 Global Urinary Tract Infection Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 30 Global Urinary Tract Infection Market Outlook, By End User (2023–2034) (\$MN)

Table 31 Global Urinary Tract Infection Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 32 Global Urinary Tract Infection Market Outlook, By Clinical Laboratories (2023–2034) (\$MN)

Table 33 Global Urinary Tract Infection Market Outlook, By Home Healthcare (2023–2034) (\$MN)

Table 34 Global Urinary Tract Infection Market Outlook, By Other End Users (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Urinary Tract Infection Market Forecasts to 2034 – Global Analysis By Product (Azoles and Amphotericin B, Cephalosporin, Nitrofurans, Penicillin and Combinations, Quinolones and Other Products), Treatment Type, Test Type, Indication, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/UFBCFCF4851CEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UFBCFCF4851CEN.html>